CD8A and cancer: For example, infiltrating CD8+ T cells are generally considered to be tumor inhibitors that are associated with a positive prognosis in most types of cancer; however, in renal cell carcinoma and prostate cancer, CD8+ T cells are reported to be associated with poor clinical outcomes [26–29].